Newcastle Disease – The business of poultry protection

In rural India and Nepal, opportunities for women to contribute to household income are scarce. However, one asset most women do have access to is backyard poultry. Families typically keep five to ten chickens, which scavenge for scraps and insects and provide a boost to household diets or income, through the sale and consumption of eggs and meat. Expanding or intensifying informal livestock rearing activities such as backyard poultry rearing is frequently advocated as a way out of poverty for rural families. But to achieve that goal, households in India and Nepal first need an affordable way to protect their birds from a widespread and highly contagious killer – Newcastle Disease (ND).

According to Peetambar Kushwaha of the Global Alliance for Veterinary Medicines (GALVmed), ND is the biggest challenge for backyard poultry production in rural and peri-urban areas, killing 80-90% of backyard chickens every year when outbreaks of the highly pathogenic strain occur. Vaccines against the disease have been available from urban veterinary stockists for many years, but are manufactured and sold in doses to meet the needs of large broiler and layer farms with thousands of birds. The vaccines are therefore beyond the reach of the backyard poultry keeper, both geographically and financially, and government campaigns for village-level vaccination, often erratic, have rarely provided adequate protection.

Appropriate and effective vaccination

GALVmed’s approach to tackling the problem involves a dual approach: a partnership with India-based vaccine manufacturer, Hester Biosciences Limited, enables the production and commercial distribution of a thermo-tolerant (i.e. heat tolerant) ND vaccine. This is important in order for the vaccine to be suitable for use in remote rural areas where transport is slow and electricity supplies are scarce and interrupted. A second feature was the production and distribution of the thermo-tolerant vaccine in much smaller doses more appropriate for the number of birds kept by backyard poultry keepers.

Supporting the development of an appropriate vaccine for backyard poultry has been key to GALVmed’s approach in tackling the problem. Apart from the issue of dose size, there was also a second priority in developing a vaccine that can be kept under a certain temperature, for a period of time without refrigeration (thermo-tolerant). This was important in order for the vaccine to be suitable for use in remote rural areas where transport is slow and electricity supplies are scarce and interrupted. A partnership with India-based vaccine manufacturer, Hester Biosciences Limited, enables the production and commercial distribution of a thermo-tolerant (i.e heat tolerant) ND vaccine, which is made available in much smaller doses, such as for 100 birds.

Photograph: James Glossop for The Times Sakuntala Shlwakoti hold a container of Newcastle Disease vaccine in the village of Khundunabayi Gabesha Chowk in Jhapa, Nepal. In the country, an Edinburgh-based charity backed by the Bill & Melinda Gates Foundation, works to improve animal health and consequently human lives through animal disease vaccination programmes. Specifically, they target Newcastle Disease, which blights backyard poultry, killing 90%+ of the flock year after year. April 2014.
Photograph: James Glossop for The Times
Sakuntala Shlwakoti hold a container of Newcastle Disease vaccine in the village of Khundunabayi Gabesha Chowk in Jhapa, Nepal.

Ensuring widespread use of the vaccine is the next part of GALVmed’s strategy. Three pilot projects, completed in 2012, proved highly successful in setting up a sustainable business model for vaccination. Rural vaccinators are recruited and trained, and are able to obtain the vaccine from local veterinary drug retailers who, informed by the project, are usually quick to appreciate the business case for stocking it. This approach is now being scaled up to serve around 300,000 farming households in six districts of Nepal and four districts in two Indian states. Over the next two and a half years, around 5 million households in three states of India will be covered through a much larger upscaling project.

In Nepal and India, an intense two years of work has seen vaccinators recruited and trained, the vaccine supply system set up and up to four rounds of vaccination completed in some areas. Two GALVmed partner organisations, Heifer International and Helen Keller International, have been responsible for the field-level implementation in Nepal. They report good results, both in terms of poultry health and the satisfaction of farmers and vaccinators with the system.

Fattepur village, on the outskirts of the city of Nepalgunj in south-western Nepal, is one site being targeted for ND control. The village is close to a forest area and has a high proportion of indigenous and marginalised people living on very low incomes. Heifer Nepal, having been working to support holistic community development in Fattepur, partnered with GALVmed to introduce ND vaccination for backyard poultry. Members of the Sayapatri women’s self-help group, for example, have been trained in housing, feeding and sanitation for poultry, and have had their birds vaccinated by a local animal health worker, trained by the NGO. A nearby ‘agrovet’ has begun to stock the vaccine, and both ND vaccination and treatment for internal parasites are now regular practices in the village. As a result, the average number of birds owned per household has increased by 3.8 times (from 5.4 to 21), and egg production over the year has increased fivefold. Average yearly earnings from sales of eggs and birds have risen from around US$48 to nearly $180 per household. This is also significant in increasing the status of the women within their families and communities.

A profitable, sustainable model

Photograph: James Glossop for The Times Sakuntala Shlwakoti vaccinates a chicken against Newcastle disease using an eye-drop in the village of Khundunabayi Gabesha Chowk in Jhapa, Nepal. In the country, an Edinburgh-based charity backed by the Bill & Melinda Gates Foundation, works to improve animal health and consequently human lives through animal disease vaccination programmes. Specifically, they target Newcastle Disease, which blights backyard poultry, killing 90%+ of the flock year after year. April 2014.
Photograph: James Glossop for The Times
Sakuntala Shlwakoti vaccinates a chicken against Newcastle disease using an eye-drop in the village of Khundunabayi Gabesha Chowk in Jhapa, Nepal.

Key to the success of the system is that it makes financial sense for the vaccinators. During the pilot phase, GALVmed found that an animal health worker needed to earn INR 5000 ($80) per month from vaccinations and other services for their business to succeed. If too many people are trained in one area, individual vaccinators are unable to earn enough money and give up. When setting up new vaccination projects, partners are therefore asked to consider factors such as the size of the target area, the number of birds and how far a vaccinator can travel in a day, in order to gauge potential earnings.

When asked about challenges, Kushwaha is more concerned about the commitment of villagers than vaccinators. “Initially, farmers are very enthusiastic about getting their birds vaccinated because their birds are dying,” he says. “But after five or six months, if they don’t see the disease, they become reluctant to vaccinate again. And if they don’t, the disease returns.” As a result, a major component of the ND control programme is to convince poultry keepers to vaccinate their birds regularly – ideally once every three months – or risk losing them. Video documentaries to help raise awareness have been produced in three languages and are shown in villages using portable video systems. These are backed up by discussion sessions, posters including murals and, in some parts of Nepal, FM radio.

GALVmed’s long-term aim is to establish a sustainable system for vaccination, based on three elements: a steady supply of vaccine in appropriate dosages and quality; a cadre of vaccinators who are trained to carry out regular rounds of vaccination; and a farming population that understands the need for regular vaccination. “Once we get that done,” says Kushwaha, “the system will run itself on a business model. Vaccine producers and retailers can make money from increased sales. Vaccinators can make money from their work, and farmers can make money from their birds.”

Written by Mike Davison, WRENmedia

Produced by WRENmedia

New drugs to fight nagana

African animal trypanosomosis (AAT), widely known in Africa as nagana, is a deadly scourge of livestock flocks and herds, killing an estimated 3 million cattle each year, as well as many sheep and goats. Spread in the bite of tsetse flies, and caused – like malaria – by a blood-dwelling parasite, the disease causes fever, severe anaemia and ultimately death if not treated. In infested areas, which cover around 10 million km2 across 40 African countries, from Senegal and Ethiopia in the north to South Africa in the south, the disease is responsible for up to 50% loss in milk and meat production.

Drugs to treat AAT are available, but efficacy is limited, particularly as there is concern over increasing disease resistance to the drugs, which were mostly developed 40-50 years ago. Another key concern is drug safety, in terms of side-effects for animal health. According to GALVmed’s Dr Rosemary Peter, if the drug companies applied today to register these AAT drugs, they would likely fail. To effectively protect and treat cattle against nagana requires the development of new drugs, which is at the heart of GALVmed’s approach, work that is being funded by the Bill and Melinda Gates Foundation and the UK Department for International Development.

Giving drug developers a head-start

Developing new drugs is, however, an expensive business. Part of GALVmed’s strategy has therefore been to absorb some of that cost, testing a range of possible drugs to identify those that demonstrate good performance in treating or protecting animals against AAT. “Once we have suitable candidates,” says Peter, “we will be approaching the big veterinary pharmaceutical companies and saying, ‘Here are some possible candidates that you can take and develop further, and then sell.’” GALVmed is thus coordinating the initial, costly work of identifying promising ‘candidates’, reducing the risk for the pharmaceutical companies, and increasing the likelihood that a finished product will reach the market.

For Dr Peter, one of the most exciting developments has been the discovery that certain drugs being tested to treat the human form of trypanosomosis (known as sleeping sickness) may be appropriate for treating animals. “We have looked at the whole library of drugs that were being tested in the context of human sleeping sickness, and found that some that weren’t very active towards the human form were very active towards the animal form of the disease,” she says. “These are the exciting ones that we are taking forward.”

The project aims to have two or three drugs to present to the pharmaceutical industry, including ideally at least one that can protect animals from infection, and one that can treat those infected. Furthermore, according to Peter, some of the candidates look very likely to go all the way to commercial manufacture, a hugely exciting prospect.

In terms of when that manufacturing might begin, the timeline is not too long. Currently, the candidate drugs are still being tested in the lab to confirm that they really are effective against the various AAT parasites. Once confirmed, they will then be put into a form that is stable and safe to test in animals, and such tests will be carried out in special, fly-proof testing facilities in Burkina Faso, Mozambique, South Africa and Ethiopia, focussing on particular regional strains of the disease. The ‘fly-proofing’ ensures that local tsetse flies cannot enter and bite the infected cattle being used in the trials to potentially infect other animals in the locality. Currently, Peter is hopeful that they will have three possible candidate drugs to present to the industry by March 2016, with full commercialisation achievable three to five years after.

Consultation and testing

Consulting a wide range of stakeholders, including livestock farmers, local vets and staff in departments of agriculture, has been an essential part of the drug development process. Through the consultation, GALVmed developed a series of ‘Target Product Profiles’ for the different drugs they are aiming to produce, itemising various features that would be either ideal (the ‘wants’) or the minimum acceptable characteristics (the ‘needs’). These included methods of administering the drug, efficacy against different strains of the disease, length of protection provided and the drug’s shelf life.

Worker , Isaiah Too herd cows to stables to be milked at the farm , Mara outside the Kenyan city of Eldoret, Monday, 8 June, 2015.GALVmed is working to protect livestock and improve human lives by making livestock vaccines, diagnostics & medicines accessible and affordable to the millions of those who rely on livestock. The organisation provides three main services: research and development of vaccinations, market development to provide vaccinations and information to livestock keepers and advocacy of its work to key stakeholders.Photo/Karel Prinsloo
Photo by Karel Prinsloo

The consultation process has also informed the development of a rapid diagnostic pen-side test for AAT – similar to that used for malaria – which can be used by a farmer to establish whether a sick animal is suffering from nagana, as opposed to another disease such as tick-bite fever. The GALVmed team has already identified a number of nagana antigens that could be testable indicators of the disease, and is currently investigating the feasibility of using these as part of a simple, farmer-administered diagnostic kit. If successful, the test would be a major step in enabling farmers to effectively target treatment for their sick animals.

Another issue that the GALVmed team is tackling is the challenge of poor quality and counterfeit AAT drugs, which are a feature of all African veterinary drug markets. Working with a number of partners[1], GALVmed has facilitated two laboratories – including equipping and training staff – in Dakar, Senegal and Dar es Salaam, Tanzania and helped to set up testing standards for drugs currently on the market. According to Peter, 40-70% of the drugs tested from West Africa and Tanzania have been found to be under-strength. As a result, the Tanzania government has now funded the lab in Dar es Salaam to carry out a further two years of testing, including of drugs against other livestock diseases where counterfeits are feared to be rife.

[1] The International Federation for Animal Health, the International Organisation for Epizootics (OIE), the International Atomic Energy Agency and the Manchester Metropolitan University

Written by Mike Davison, WRENmedia

Produced by WRENmedia